Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of 300 IR house dust mite SLIT tablets in children and adolescents with allergic rhinitis
2009-011999-30Phase 3Terminated
- Sponsor
- Stallergenes Greer
- Start
- Jun 2009
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in house dust mite allergic rhinitis and allergic rhinitis (AR) comparing 300 IR HDM SLIT tablet with Placebo (2 arms). Primary endpoint: Average Adjusted Symptom Score. Started Jun 2009; status: terminated.
02
Drugs
House dust mite allergen extract
03
Conditions
house dust mite allergic rhinitisallergic rhinitis (AR)
Beyond the preview
Go deeper on 2009-011999-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011999-30.